Literature DB >> 26170570

Fluoro-deoxy glucose positron emission tomography-computed tomography in a case of natural killer/T-cell lymphoma with bilateral adrenal involvement.

Chidambaram Natrajan Balasubramanian Harisankar1.   

Abstract

Natural killer/T-cell (NK/T-cell) lymphoma is a rare condition, which presents as necrotic, granulomatous lesions involving the nose and the upper respiratory tract. The condition usually has an aggressive clinical course. The predominant subtype of NK/T-cell lymphoma noted in Asian population is the nasal type. We describe a case of biopsy-proven NK/T-cell lymphoma with bilateral adrenal involvement. Adrenal involvement by lymphoma is usually of B-cell type and occurs in disseminated disease and often unilateral. Bilateral adrenal involvement by T-cell lymphoma is extremely rare.

Entities:  

Keywords:  Adrenal lymphoma; SMILE; fluoro-deoxy glucose positron emission tomography-computed tomography; midline granuloma; natural killer/T-cell lymphoma

Year:  2015        PMID: 26170570      PMCID: PMC4479916          DOI: 10.4103/0972-3919.158537

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


INTRODUCTION

Natural killer/T-cell (NK/T-cell) lymphoma is a rare fast-growing lymphoma arising from the lining of the nose or upper airway. They usually present with epistaxis and swelling. We report an interesting case who also had bilateral adrenal involvement.

CASE REPORT

A 26-year-old young female presented with nasal obstruction, bloody discharge and swelling of the nasal skin and right lower eyelid. Biopsy from the soft tissue seen in the nasal cavity revealed NK/T-cell lymphoma (nasal type). Patient was referred to a whole body 18 fluoride (18F)-fluoro-deoxy glucose (FDG) positron emission tomography-computed tomography (PET-CT). 18F-FDG PET-CT performed showed intense FDG uptake in heterogeneously enhancing soft tissue in the right nasal cavity with extension into the skin of the cheek and right lower eyelid [Figure 1: a - maximum-intensity projection, b - axial CT, c - fused PET-CT]. Intense FDG uptake was also noted in enhancing soft tissue bilateral adrenal masses [d - axial CT; e - fused PET-CT] indicating disease involvement. A diagnosis of bilateral adrenal involvement by NK/T-cell lymphoma was made. Patient was referred back to medical Oncology Department for chemotherapy.
Figure 1

18 Fluoride-fluoro-deoxy glucose positron emission tomography-computed tomography (18F-FDG PET-CT) performed showed intense FDG uptake in heterogeneously enhancing soft tissue in the right nasal cavity with extension into the skin of the cheek and right lower eye lid (a - maximum-intensity projection, b - axial CT, c - fused PET-CT). Intense FDG uptake was also noted in enhancing soft tissue bilateral adrenal masses (d - axial CT; e - fused PET-CT) indicating disease involvement

18 Fluoride-fluoro-deoxy glucose positron emission tomography-computed tomography (18F-FDG PET-CT) performed showed intense FDG uptake in heterogeneously enhancing soft tissue in the right nasal cavity with extension into the skin of the cheek and right lower eye lid (a - maximum-intensity projection, b - axial CT, c - fused PET-CT). Intense FDG uptake was also noted in enhancing soft tissue bilateral adrenal masses (d - axial CT; e - fused PET-CT) indicating disease involvement

DISCUSSION

Natural killer cells mediate lysis of tumor cells, bacteria or virus infected cells. They also aid in the production of immunomodulatory cytokines. Morphologically, mature NK cells are large granular lymphoid cells, they are negative for surface CD3 but characteristically express cytoplasmic CD3 epsilon (ε), CD56, and cytotoxic molecules. There are two main categories of NK cell-derived neoplasms, namely, aggressive NK cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Epstein–Barr virus infection in the lymphoma cells is a consistent finding.[1] NK/T-cell lymphoma of the nasal type accounts for 7–10% of all non-Hodgkin lymphomas in Asia and Latin America, but only 1% of that amongst Caucasians.[2] The leukemic counterpart of NK/T-cell lymphoma, aggressive NK-cell leukemia is an uncommon disease. Clinically, it is useful to classify NK/T-cell malignancies into two categories, namely, nasal NK-cell lymphomas, and nonnasal or extranasal NK/T-cell lymphomas, depending on the site of the lesions. Nasal NK/T-cell lymphomas occur in the nose and the upper aerodigestive tract. Nasal obstruction, facial swelling, and epistaxis are the common presentations. Bone marrow involvement occurs in <10% of patients, and distant metastasis is unusual.[3] Extranasal or nonnasal NK/T-cell lymphomas occur outside the typical nasal region, and the common primary sites involved include the skin, gastrointestinal tract, salivary glands, spleen, and testis. Unusual sites of involvement such as the muscle, the adrenal gland, and the female genital tract (ovaries and uterus) have been reported.[4] Occult nasal involvement should be ruled out with panendoscopy and multiple random biopsies in patients presenting with extranasal NK/T-cell lymphoma. Disseminated nodal NHL can involve the adrenals in up to 25% of the cases.[56] However, primary adrenal lymphoma is extremely rare with majority of the cases being B cell type. Natural killer-cell lymphomas are FDG-avid and PET-CT offers more accurate definition of the extent of involvement by distinguishing lymphoma involvement from inflammatory masses. 18-FDG PET-CT is increasingly used both at diagnosis and for monitoring of response to therapy.[789] PET changes the staging in up to 21% of the patients and alters the planned management strategy in 44% of the patients.[7] PET parameters such as total lesion glycolysis, in addition to the international prognostic index, is useful in predicting prognosis of these patients.[9] For the stage, I/II nasal NK/T-cell lymphomas, radiotherapy is an important modality of treatment. Recent evidence indicates radiation therapy alone is insufficient, and chemotherapy is also needed in these patients. Nonnasal NK cell lymphomas tend to have advanced or disseminated disease at presentation, and the role of radiotherapy is often limited. For the stage III/IV nasal NK/T-cell lymphomas, extranasal NK/T-cell lymphomas and aggressive NK-cell lymphoma/leukemia, chemotherapy is the primary treatment. L-asparaginase-containing regimens have shown promise as the tumor cells lack L-asparagine synthetase and are susceptible to L-asparaginase, which depletes L-asparagines in NK lymphoma cells.[10]
  10 in total

1.  The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.

Authors:  Seung Hwan Moon; Suk Kyong Cho; Won-Seog Kim; Suk Jin Kim; Yong Chan Ahn; Yearn Seong Choe; Kyung-Han Lee; Byung-Tae Kim; Joon Young Choi
Journal:  J Nucl Med       Date:  2013-05-08       Impact factor: 10.057

2.  Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma.

Authors:  Choon-Young Kim; Chae Moon Hong; Do-Hoon Kim; Seung Hyun Son; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

3.  (18)F-FDG PET/CT in bilateral primary adrenal T-cell lymphoma.

Authors:  Sampath Santhosh; Bhagwant Rai Mittal; Praveen Shankar; Raghava Kashyap; Anish Bhattacharya; Baljinder Singh; Ashim Das; Anil Bhansali
Journal:  Hell J Nucl Med       Date:  2011 May-Aug       Impact factor: 1.102

Review 4.  FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature.

Authors:  Rakesh Kumar; Yan Xiu; Ayse Mavi; Ghassan El-Haddad; Hongming Zhuang; Abass Alavi
Journal:  Clin Nucl Med       Date:  2005-04       Impact factor: 7.794

5.  Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years.

Authors:  W-Y Au; S-Y Ma; C-S Chim; C Choy; F Loong; A K W Lie; C C K Lam; A Y H Leung; E Tse; C-C Yau; R Liang; Y-L Kwong
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

6.  Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.

Authors:  Pek-Lan Khong; Bingsheng Huang; Elaine Yuen Phin Lee; Winnie Kit Sum Chan; Yok-Lam Kwong
Journal:  J Nucl Med       Date:  2014-05-12       Impact factor: 10.057

7.  Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type.

Authors:  Li Yang; Hong Liu; Xiao-hong Xu; Xin-feng Wang; Hong-ming Huang; Wen-yu Shi; Sheng-hua Jiang
Journal:  Med Oncol       Date:  2013-09-24       Impact factor: 3.064

8.  Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type.

Authors:  F C Ho; G Srivastava; S L Loke; K H Fu; B P Leung; R Liang; D Choy
Journal:  Hematol Oncol       Date:  1990 Sep-Oct       Impact factor: 5.271

9.  NK-cell lymphomas and leukemias: a spectrum of tumors with variable manifestations and immunophenotype.

Authors:  Robert P Hasserjian; Nancy Lee Harris
Journal:  Am J Clin Pathol       Date:  2007-06       Impact factor: 2.493

10.  Extranodal natural-killer/t-cell lymphoma, nasal type.

Authors:  Harinder Gill; Raymond H S Liang; Eric Tse
Journal:  Adv Hematol       Date:  2010-12-30
  10 in total
  2 in total

1.  Unilateral primary adrenal natural killer/T-cell lymphoma: Role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography for staging and interim response assessment.

Authors:  Rasika Kabnurkar; Archi Agrawal; Sridhar Epari; Nilendu Purandare; Sneha Shah; Venkatesh Rangarajan
Journal:  Indian J Nucl Med       Date:  2016 Jan-Mar

Review 2.  Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma.

Authors:  Jian-Jun Ding; Ya-Lian Chen; Shui-Hong Zhou; Kui Zhao
Journal:  J Int Med Res       Date:  2018-10-17       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.